Myrobalan raises $24M round to bring central nervous system drug into clinic

A biotech developing an oral drug to repair damage and restore neural function in patients with such conditions as Alzheimer ’s disease, ALS and multiple sclerosis has raised a round of venture capital. Myrobalan Therapeutics of Medford, Mass. announced a $24 million Series A investment round on Wednesday morning. The round was led by Co-win Healthcare Fund of China, alongside new and existing investors, including 3E B ioventures Capital, AB Magnitude Ventures Group and Guan Zi Equity Investment…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news